1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

Since the discovery of sickle cell disease (SCD) in 1910, enormous strides have been made
in the elucidation of the pathogenesis of its protean complications, which has inspired recent …

Background Sickle cell disease is characterized by the painful recurrence of vaso-occlusive
events. Gene therapy with the use of LentiGlobin for sickle cell disease (bb1111; …

Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB,
which encodes haemoglobin subunit β. The incidence is estimated to be between 300,000 …

Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

Sickle cell anaemia is one of the groups of inherited disorders known as sickle cell disease
and it affects the shape of red blood cells, which carry oxygen to all parts of the body. Sickle …

Deformability is an essential feature of blood cells (RBCs) that enables them to travel
through even the smallest capillaries of the human body. Deformability is a function of (i) …

The use of messenger RNA (mRNA) in gene therapy is increasing in recent years, due to its
unique features compared to plasmid DNA: Transient expression, no need to enter into the …

Background Hydroxyurea is an effective treatment for sickle cell anemia, but few studies
have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting …

Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso‐
occlusive crises (VOCs). Data on the global SCD impact on quality of life (QoL) from the …